Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Zilovertamab vedotin showed a distinct plasma concentration profile over time in participants.
• The study utilized intravenous administration every three weeks to assess total antibody pharmacokinetics.
• Phase 2 design allowed for detailed examination of drug behavior in a targeted patient population.
• These findings may impact future treatment strategies for metastatic solid tumors.